Lymphoid tissue
Hodgkin lymphoma
A lymphoma in which a few large neoplastic Reed-Sternberg cells drive a mass of reactive cells; it spreads contiguously from node group to node group, so staging guides treatment.
Causes et facteurs de risque
- Neoplastic Reed-Sternberg cells; EBV DNA is found in some patients
Aspect macroscopique
- Enlarged, non-tender lymph nodes with a lobulated tan-pink cut surface (a normal node is soft and under 1 cm).
- It may involve one node, a group, many groups, or extranodal sites such as spleen, liver and marrow.
Au microscope
- Reed-Sternberg cells (only 1–5% of the mass): large, often bilobed with mirror-image “owl-eye” nuclei and huge nucleoli.
- They express PAX5, CD15 and CD30 but not CD20 or CD45.
- A background of reactive lymphocytes, macrophages, eosinophils and fibroblasts; lacunar cells in the nodular sclerosis type.
Évolution
- Reed-Sternberg cells secrete cytokines (IL-5, IL-6, IL-13, TNF, GM-CSF).
- These draw in the reactive cells that make up most of the tumour.
- The disease spreads contiguously from one lymph node region to the next, and later to extranodal sites.
Complications
- “B” symptoms in about 40%: fever, night sweats, weight loss; some have pruritus, or pain at involved sites after alcohol
- Reduced cell-mediated immunity, with more frequent and severe infections
- After treatment, about 5% develop myelodysplasia, acute myeloid leukaemia or carcinomas
Examens complémentaires
- Lymph node excision biopsy
- Reed–Sternberg cells in a background of reactive cells; they are CD15 and CD30 positive and usually CD45 negative.
- CT or PET-CT
- Stages the disease: which node groups are involved and whether the spleen or other organs are.
- Blood tests
- Full blood count (eosinophilia, anaemia), ESR and LDH, which reflect disease activity.
Traitement médicamenteux
- Systemic corticosteroids (glucocorticoids): Powerful anti-inflammatory and immunosuppressive hormones acting on nuclear receptors: used for flares of inflammatory bowel disease, asthma attacks, brain-tumour oedema and many other conditions, at the price of wide-ranging adverse effects.
- Antitumour antibiotics (anthracyclines and bleomycin): Cytotoxic drugs from Streptomyces: anthracyclines (doxorubicin) intercalate DNA and poison topoisomerase II, used in breast cancer, lymphomas and sarcomas but toxic to the heart; bleomycin breaks DNA with free radicals and scars the lungs.
- Alkylating agents (cyclophosphamide, temozolomide, dacarbazine): Drugs that attach alkyl groups to DNA, cross-linking or mispairing it; cyclophosphamide is used in breast cancer and lymphomas, temozolomide in glioblastoma, dacarbazine in Hodgkin lymphoma.
- Microtubule inhibitors (vinca alkaloids and taxanes): Drugs that disrupt the mitotic spindle so cells cannot divide: vinca alkaloids stop microtubules forming, taxanes stop them breaking down. Used in lymphomas, breast and lung cancer; neuropathy is the shared toxicity.
- Immune checkpoint inhibitors: Antibodies that release the brakes on T cells (PD-1, PD-L1, CTLA-4) so the immune system attacks the tumour; they transformed melanoma, renal cell, lung and liver cancer and Hodgkin lymphoma, but can trigger autoimmune damage to any organ.
Anatomie concernée
Rédigé d’après
- Robbins and Cotran Atlas of Pathology, 3rd ed., Ch. 3, Hematopathology, pp. 78–79, figs 3-42 to 3-47
Ressource pédagogique. Ne constitue pas un avis, un diagnostic ou un traitement médical.